USPTO Trademark 99518157
USPTO Trademark 99518157 is a USPTO trademark filed by Vertex Pharmaceuticals Incorporated. Status: Pending.
Prosecution Summary
Trademark Summary
The mark is a color design featuring an arc with a burst of lines deflecting from the arc in shades of aqua, pink, magenta, and purple. It covers pharmaceutical preparations in International Class 005 for treating immune system diseases, autoimmune disorders, immunoglobulin A nephropathy, primary membranous nephropathy, lupus nephritis, renal anti-neutrophil cytoplasmic antibody-associated vasculitis, immune thrombocytopenia, cold and warm autoimmune hemolytic anemia, kidney diseases, blood diseases, and inflammation-related diseases, plus goods/services in U.S. classes 006, 018, 044, 046, 051, and 052. The application is owned by Vertex Pharmaceuticals Incorporated, a Massachusetts corporation. It is a
Trademark Facts
| Mark | USPTO Trademark 99518157 |
|---|---|
| Serial Number | 99518157 |
| Status | Pending |
| Filing Date | 2025-11-26 |
| Mark Type | Design |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Vertex Pharmaceuticals Incorporated |
| Attorney of Record | Lisa M. Tittemore |
| Prosecution Events | 13 |
| Latest Event | GNRT on 2026-04-22 |
Goods & Services
Class 005: Pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of autoimmune diseases and disorders; pharmaceutical preparations for the treatment of immunoglobulin A nephropathy; pharmaceutical preparations for the treatment of primary membranous nephropathy; pharmaceutical preparations for the treatment of lupus nephritis; pharmaceutical preparations for the treatment of renal anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis; pharmaceutical preparations for the treatment of immune thrombocytopenia; pharmaceutical preparations for the treatment of immune thrombocytopenia purpura; pharmaceutical preparations for the treatment of cold autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of warm autoimmune hemolytic anemia; pharmaceutical preparations for the treatment of kidney diseases and disorders; pharmaceutical preparations for the treatment of blood diseases and disorders; pharmaceutical preparations for the treatment of inflammation related diseases and disorders
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-04-22 | Non-Final Action | NFIN |
| 2026-04-22 | Notice of Non-Final Office Action | NFO |
USPTO Refusals on Record
- indefinite_identification